Processing of human immunodefi ciency virus (HIV) proteins by the HIV-1 protease is essential for HIV infectivity. In addition, several studies have revealed cleavage of human proteins by this viral protease during infection; however, no large-scale HIV-1 protease degradomics study has yet been performed. To identify putative host substrates in an unbiased manner and on a proteome-wide scale, we used positional proteomics to identify peptides reporting protein processing by the HIV-1 protease, and a catalogue of over 120 cellular HIV-1 protease substrates processed in vitro was generated. This catalogue includes previously reported substrates as well as recently described interaction partners of HIV-1 proteins. Cleavage site alignments revealed a specifi city profi le in good correlation with previous studies, even though the ELLE consensus motif was not cleaved effi ciently when incorporated into peptide substrates due to subsite cooperativity. Our results are further discussed in the context of HIV-1 infection and the complex substrate recognition by the viral protease.
Introduction
Many pathogens encode their own protease(s) or use host proteases for their replication cycle. For the human immunodefi ciency virus-1 (HIV-1), causing the acquired immunodefi ciency syndrome (AIDS) pandemic, the processing of the viral Gag and Gag-Pol polyprotein precursors to generate the mature Gag and Pol proteins is well described (Freed , 2001 ) . These processing events are catalyzed by the HIV-1 protease, a homodimeric aspartic protease, and take place during or shortly after virion release from the plasma membrane in a process called virus maturation. Failure of the HIV-1 virion to mature properly is associated with a complete loss of infectivity (Kohl et al. , 1988 ) ; therefore, HIV-1 protease inhibitors are amongst the most effective protease inhibitor drugs used in health care (Drag and Salvesen , 2010 ) .
Next to the processing of viral proteins, several host cell proteins have also been identifi ed as substrates of the HIV-1 protease. In fact, according to the HIV-1 Human Protein Interaction Database at NCBI [http://www.ncbi.nlm.nih.gov/ RefSeq/HIVInteractions/ (Fu et al. , 2009 ) ], more than 60 human proteins are known to be cleaved by the viral protease (interaction types ' cleaves, ' ' degrades ' or ' activates ' ). One example is the cleavage of human procaspase-8, which results in caspase activation and the induction of apoptosis in infected cells (Nie et al. , 2002 (Nie et al. , , 2007 (Nie et al. , , 2008 . Another example is the processing of eukaryotic translation initiation factor 4 gamma 1 (eIF4GI) and polyadenylate-binding protein 1 (PABP), which may lead to inhibition of cellular protein synthesis by blocking cap-and poly(A)-dependent initiation of translation in infected cells (Castello et al. , 2009 ) . Although host proteins might not be the primary substrates for the HIV-1 protease, these data indicate that the processing of host cell factors should be considered as more than just bystander events given the potentially profound effect on cellular homeostasis.
At present, no studies have yet been undertaken to systematically identify cellular substrates of the HIV-1 protease. A recent interactomics screen identifi ed 54 human proteins as interaction partners of a catalytically inactive variant of the HIV-1 protease; however, only the eukaryotic translation initiation factor 3 subunit D (eIF3D) was confi rmed as a substrate of the wild-type protease (Jager et al. , 2012 ) . As the current data on protein processing of host proteins during HIV-1 infection result from rather scattered studies, we opted for a large-scale positional proteomics approach to expand the present knowledge on putative host cell HIV-1 protease substrates. Several proteomics-based methods were developed to screen for protease cleavage events in complex samples [also referred to as degradomics (Lopez -Otin and Overall, 2002 ) ], and one of these is the N-terminal COFRADIC technology developed in our lab (Gevaert et al. , 2003 ; Staes et al. , 2008 Staes et al. , , 2011 . In contrast to shotgun proteomics, these technologies specifi cally isolate and identify protein terminal peptides and, thus, also neo-N-terminal peptides generated upon protease cleavage that serve as proxies to identify protease processing events [reviewed in (Impens et al. , 2010a ) ].
Here, we used N-terminal COFRADIC to screen for protein processing in lysates of human Jurkat T-cells that were incubated in vitro with recombinant HIV-1 protease. We identifi ed more than 140 HIV-1 protease cleavage sites in about 120 host proteins, including known substrates such as actin and eIF3D (Tomasselli et al. , 1991 ; Jager et al. , 2012 ) . Many substrates are involved in protein translation or are known interaction partners of HIV-1 proteins. Cleavage site alignments further showed a subsite-specifi city profi le corresponding to previous observations, but did not allow delineation of an effi ciently cleaved consensus motif.
Results

Experimental setup
To identify putative novel host cell substrates of the HIV-1 protease, we incubated freeze-thaw lysates of Jurkat T-cells with recombinant HIV-1 (rHIV-1) protease. As this protease is more active under conditions of high ionic strength and low pH, a buffer containing 300 m m NaCl at pH 5.5 was used (Wondrak et al. , 1991 ) . Different protease concentrations and incubation times were fi rst tested by monitoring the processing of vimentin, a known HIV-1 protease substrate (Shoeman et al. , 1990 ) (Figure 1 ). Incubation of the Jurkat cell lysate for 60 min with 200 n m rHIV-1 protease led to almost complete vimentin processing, which was prevented by the HIV-1 protease inhibitor Ac-pepstatin, but not by the pan-caspase inhibitor zVADfmk. Based on these results, we decided to screen for processing events in lysates treated for 75 min with 200 n m rHIV-1 protease in the presence of 50 μ m zVADfmk. The latter was added to inhibit possible activated caspases and thus to prevent detection of caspase-induced processing events (Nie et al. , 2002 (Nie et al. , , 2007 (Nie et al. , , 2008 .
The COFRADIC proteomics technology was used to isolate N-terminal peptides, including those generated by protease-mediated processing (Gevaert et al. , 2003 ) . In addition, stable isotope labeling by amino acids in cell culture (SILAC) labeling (Ong et al. , 2002 ) with arginine residues was used to compare a protease-treated sample ( 12 C 6 -Arg) with a control sample ( 13 C 6 -Arg). As such, identifi cation of newly formed N-termini by the HIV-1 protease was straightforward as such peptides were only picked up in their 12 C 6 -Arg form (Figure 2 ), different from other identifi ed proteins that are not substrates. To increase the overall coverage of identifi ed cleavage sites, the experiment was repeated three times. In total, we identifi ed 148 rHIV-1 protease cleavage sites in 123 proteins (Table 1 ) .
HIV-1 protease in vitro processed host substrates
The number of substrates identifi ed in our screen almost doubles the number of host cell proteins that are known to be cleaved by the HIV-1 protease (Fu et al. , 2009 ) . Nevertheless, to our knowledge, only two proteins were previously reported as substrates of the viral protease. In the cytoskeletal protein actin we picked up three cleavage sites, one of which (between Leu 105 and Thr 106) was reported by Tomasselli et al. (1991) more than 20 years ago (Figure 3 ). In contrast, the processing of eIF3D was described recently by Jager et al. (2012) and found to occur between Met 114 and Leu 115, a position close to the one reported here (between Gln 120 and Ile 121). In the latter study, eIF3D was identifi ed as a high confi dence interaction partner of a catalytically inactive variant of the HIV-1 protease, together with 53 other human proteins. Interestingly, two of these proteins were also confi rmed in our screen as substrates of the HIV-1 protease. Moreover, we found that seven host proteins reported as high confi dence interaction partners of other HIV-1 proteins are also substrates of the HIV-1 protease [ (Jager et al. , 2012 ) and Table 1 ].
Given the in vitro nature of the experiment using total cell lysates, it is not surprising that substrates were derived from different cellular locations as revealed by gene ontology analysis using PIGOK (Jacob and Cramer , 2006 ) . Substrates were distributed over the nucleus, cytoplasm and mitochondria, similar to all human proteins identifi ed in our screen (including non-substrates) and all human proteins present in the Swiss-Prot database (Figure 4 , top panel). Almost no substrates were annotated to be part of the endoplasmic reticulum, Golgi apparatus, lysosomes or plasma membrane. RNA-binding proteins were clearly enriched among the substrates, including several ribosomal proteins, ribonucleoproteins, RNA helicases and splicing factors. No such enrichment was observed for DNA-binding proteins, which is refl ected in the higher fraction of substrates involved in translation compared to transcription (Figure 4 , bottom panel). Further, visualization of functional interactions between substrate proteins using STRING (Jensen et al. , 2009 ) pointed to ribosomal proteins and spliceosome components as two major clusters of RNA-binding proteins in our dataset (data not shown). 
Figure 1
Immunoblot-based optimization of protease concentration and incubation time by monitoring degradation of the known HIV-1 protease substrate vimentin (Ac-pepstatin: HIV-1 protease inhibitor; zVADfmk: pan-caspase inhibitor). Progressive vimentin processing was observed with increasing protease concentration and incubation time. Addition of Ac-pepstatin blocked this process, whereas the addition of zVADfmk had no effect. 2011 ). Several DDX5 fragments were observed when HIV-1 protease was added to Jurkat cell lysates, and DDX5 processing was prevented by ritonavir, a potent HIV-1 protease inhibitor ( Figure 5 ). The size of the major DDX5 fragment observed matched with the expected molecular weight of the newly formed C-terminal fragment based on the DDX5 cleavage site found here (58 kDa, note that the antibody epitope is situated near the C-terminus of the protein), whereas lower MW bands probably indicate secondary cleavage products by host proteases.
HIV-1 protease cleavage site specifi city
Information about cleavage site specifi city of the HIV-1 protease was extracted using iceLogo ). This software tool was used to visualize cleavage site alignments and compare the amino acid frequency at positions before and after the cleavage site to their frequency found in all human proteins stored in the Swiss-Prot database (background control). Signifi cantly over-or underrepresented residues are then depicted at the top or the bottom of the iceLogo, respectively. IceLogo representation of all cleavage sites identifi ed in our screen showed an overall high overlap with the iceLogo obtained from 327 cleavage sites in peptide substrates that were reported using another proteomics approach, PICS (Schilling and Overall , 2008 ) , which indicates no major differences in cleavage site specifi city upon processing of protein and peptide substrates ( Figure 6 ). Both iceLogos show an enrichment of residues two positions before and after the cleavage site (P2 to P2 ′ ), whereas positions beyond this region are clearly less important for cleavage site recognition, in line with previous observations (Beck et al. , 2000 (Beck et al. , , 2002 . The enriched amino acids correspond well with the literature and show a striking symmetry between primed and unprimed sites that fi ts with the homodimeric nature of the protease (Tozser and Oroszlan , 2003 ) . Whereas at P2 and P2 ′ , negatively charged and hydrophobic, β-branched residues are preferred, large non-β branched hydrophobic and aromatic residues are enriched at P1 and P1 ′ (Beck et al. , 2000 (Beck et al. , , 2002 ( Figure 6 ). Basic residues, as well as glycine and proline, are generally disfavored at all four positions. At P2, arginine residues were completely absent in both COFRADIC and PICS datasets (depicted pink at the lower part of the iceLogo). The same is true for proline residues at P1; however, the latter residue is allowed at the P1 ′ position, a rather unique feature of the HIV-1 protease required to cleave several sites in the viral polyproteins (Tozser and Oroszlan , 2003 ) .
To test whether the palindromic consensus motif ELLE is effi ciently cleaved by the HIV-1 protease, we incorporated the sequence into synthetic peptides and compared it with the IFLE-motif that was found to be the optimal sequence using phage display libraries (Beck et al. , 2000 ) . Fluorescently quenched peptides were initially used, and their processing was monitored by fl uorimetry. However, signifi cant inner fi lter effects interfered with these analyses, and therefore RP-HPLC separations of precursor peptides and their fragments were performed ( Figure 7 ). The GEL ELLE LKDG peptide represents the consensus sequence of the COFRADIC sites, the Light ( 12 C 6 ) and heavy ( 13 C 6 ) arginine SILAC-labeled Jurkat T-cells were incubated with 200 n m rHIV-1 protease and buffer, respectively, for 75 min at 37 ° C, following which both proteomes were mixed in a 1:1 ratio. Subsequent trypsin digestion resulted in a mixture of internal, N-terminal and neo-N-terminal peptides. N-terminal COFRADIC (Gevaert et al. , 2003 ; Van Damme et al. , 2008 ; Staes et al. , 2008 Staes et al. , , 2011 was then used to isolate N-terminal and neo-Nterminal peptides prior to LC-MS(/MS) analysis, leading to MS-spectra showing one (light, neo-N-terminal peptides) or two (light and heavy, protein N-terminal peptides) isotopically labeled peptides.
Using Western blotting, we confi rmed HIV-1 protease mediated processing of the probable ATP-dependent RNA helicase DDX5 (DDX5), a host RNA helicase involved in gene transcription and RNA splicing (Fuller -Pace and Moore, Peptides are ranked by the Swiss-Prot annotated name of their corresponding proteins and by increasing cleavage site position. Columns from left to right contain the Swiss-Prot accession number of the substrate protein, the sequence of the identifi ed neo-N-terminal peptide, the start and end position of the peptide in the protein sequence, m/z, charge (z), delta m/z, Mascot score and threshold of the best scoring MS/MS spectrum (95 % confi dence level), the number of MS/MS spectra by which the neo-N-terminal peptide was identifi ed in the individual experiments, the protein name, the actual cleavage site position including the surrounding amino acid sequence, possible protein isoforms in which the same peptide sequence can be found and the HIV protein the substrate was found to interact with by Jager et al. (2012) . Table 1 (Continued) Figure 3 Identifi cation of the known HIV-1 protease cleavage site in actin between Leu 105 and Thr 106. Two different peptides from actin were identifi ed: actin ' s N-terminal peptide, 2-DDDIAALVVDNGSGMCKAGFAGDDAPR-28 (N-terminus acetylated, lysine trideutero-acetylated, methionine oxidized and cysteine carbamidomethylated) was present in both light and heavy labeled proteome digests (left ion trap MS spectrum of its triply charged precursor), and a second peptide that was only present in the heavy labeled cell lysate treated with HIV-1 protease (middle ion trap MS spectrum of its doubly charged precursor). Upon MS/MS analysis (right MS/MS spectrum, b and y fragment ions indicated), this peptide was identifi ed as 106-TEAPLNPKANR-116 (N-terminus and lysine were both trideuteroacetylated) and pointed to a previously reported cleavage site of the HIV-1 protease (Tomasselli et al. , 1991 ) .
GSG IFLE TSLY peptide was previously reported by Beck et al. (2000) as an optimal substrate for the HIV-1 protease, and GSG ELLE TSL contains the ELLE-motif surrounded by the residues of the sequence reported by Beck et al. Remarkably, much less effi cient cleavage of the ELLE-motif was observed, even though Ile at P2 and Phe at P1 showed lower degrees of enrichment in both iceLogos compared to Glu and Leu at these positions ( Figure 6 ).
Discussion
We here provide a catalogue of 123 human proteins cleaved in vitro by the HIV-1 protease. This host substrate list was generated by incubating lysates of human Jurkat T-cells with recombinant HIV-1 protease, followed by identifi cation of neo-N-terminal, proteolysis-reporter peptides by mass spectrometry. In this way, information on both substrate identity and exact cleavage site location was obtained.
Two proteins on our list were reported before as substrates of the HIV-1 protease. Although this overlap might seem small, it validates our approach and its results, and it should further be noted that certain cleavage sites might be missed by mass spectrometry-based degradomics screens for different reasons. Obviously, processing should result in protein fragments and neo-N-terminal peptides that are stable and identifi able by mass spectrometry. In the case of vimentin, four HIV-1 protease cleavage sites have been reported (Shoeman et al. , 1990 ) , but three of these sites will lead to tryptic neo-Nterminal peptides that are too short to allow confi dent identifi cation. Furthermore, only a fraction of the peptides injected on LC-MS/MS instruments will be fragmented for identifi cation, a phenomenon generally known as undersampling (Liu et al. , 2004 ) . Interestingly, ten of the identifi ed substrates recently came out of an interactomics study as host interaction partners of HIV-1 proteins (Jager et al. , 2012 ) . This overlap suggests an interesting and unexpected interplay between the viral protease, the web of its host cell substrates and other HIV-1 proteins. PIGOK (GO) analysis revealed that our substrate catalogue is enriched for RNA-binding proteins often involved in RNA splicing and protein translation. The latter observation suggests that modulation of protein translation during infection is probably achieved by proteolytic processing of additional host factors other than eIF4GI , eIF3D and PABP (Castello et al. , 2009 ; Jager et al. , 2012 ) . We further validated our substrate catalogue by confi rming DDX5 as an in vitro substrate of the HIV-1 protease by western blot. Interestingly, DDX5 was recently found to be associated with the HIV-1 Rev protein by co-immunoprecipitation, and silencing of this host RNA helicase in reporter HeLa cells strongly increased viral production and virion infectivity (Naji et al. , 2012 ) . It might be worth further investigating if proteolytic inactivation of host DDX5 is a strategy used by the virus to enhance its own infectivity and replication.
In contrast to consensus sequences derived from catalogues of caspases, granzymes and cathepsins (Demon et al. , 2009 ; Van Damme et al. , 2009 ; Impens et al. , 2010b ) , we did not observe effi cient cleavage of the iceLogo-suggested 
Figure 4
Substrate Gene Ontology analysis using PIGOK (Jacob and Cramer , 2006 ) . Gene ontology annotation was compared for all human proteins present in the Swiss-Prot database (black bars), all proteins identifi ed in our screen (substrates and non-substrates, dark grey bars) and all identifi ed substrates (light grey bars). Substrates were distributed over different cellular compartments as expected (top), but showed a remarkable enrichment of RNA-binding proteins involved in translation but not of DNA-binding proteins and proteins involved in transcription. (Table 1) .
ELLE-motif when tested in peptide substrates (Figure 7) . We attribute this observation to subsite cooperativity [a substrate residue at one subsite infl uencing the binding of residues at other positions (Ng et al. , 2009 ) ], which has been described for the HIV-1 protease (Tozser and Oroszlan , 2003 ) . A similar observation was recently reported for astacin proteases where the presence of Asp at P1 ′ and Pro at P2 ′ was found to be mutually exclusive when incorporated into peptide substrates. Also in this study, Asp and Pro were preferred residues at the P1 ′ and P2 ′ positions as revealed by sequence logo representation (Becker -Pauly et al., 2011 ) . In the case of the HIV-1 protease, several types of cooperativity have been suggested, with cis and trans interactions between subsites located on the same or opposite subunits, respectively, and coupled interactions infl uence binding in multiple adjacent subsites (Ridky et al. , 1996 ; Tozser et al. , 1997; Tozser and Oroszlan, 2003 ) . We believe that trans cooperativity between the P1 and P2 subsites is responsible for the difference in cleavage observed between the IFLE and ELLE motifs, in line with previous observations (Ridky et al. , 1996 ) . In the complete dataset, Glu (20.3 % ) and Leu (25.7 % ) are the most observed amino acids at P2 and P1, respectively, whereas Ile (12.2 % ) and Phe (11.5 % ) show an overall lower abundance at these positions (Supplementary Table 1 ). However, when only considering sites with a P2 Glu, the presence of both P1 Leu (20.0 % ) and P1 Phe (6.7 % ) residues is decreased with about 5 % , which is not the case for sites with a P2 Ile [P1 Leu (27.8 % ) and P1 Phe (11.1 % )]. This cooperativity is reciprocal, as sites with a P1 Leu and P1 Phe both show a decrease in P2 Glu (respectively, 15.8 % and 11.8 % ) , whereas, in the presence of P2 Ile, these frequencies are largely unchanged (13.2 % and 11.8 % , respectively). In general, our data indicate that mainly P2 ′ Glu residues are involved in positive interactions with the adjacent subsites (P1 and P1 ′ ), whereas the inverse is true for P2 Glu residues (Supplementary Table 1 ). It should further be noted that both tested motifs (i.e., IFLE and ELLE) were never observed in any of the identifi ed cleavage sites. Unlike the ELLE sequence, processing sites in the Gag and Gag-Pol polyproteins are structurally asymmetric and crystallographic studies with peptides containing these sites showed that the viral protease achieves its substrate specifi city by recognition of shapes and volumes rather than specifi c amino acids (Prabu -Jeyabalan et al., 2002 ) . A previous study with palindromic peptide substrates also showed no obvious symmetrical preference of the HIV-1 protease (Tozser et al. , 1997 ) . Moreover, recent studies have shown that substrate dynamics (Ozen et al. , 2011 ) and interactions outside the active site cleft infl uence substrate cleavage (Lee et al. , 2012 ) , phenomena that are ignored by sequence site alignments using tools such as iceLogo. Finally, it should be mentioned that we could only partially confi rm cooperativity between the P3 and P2 positions that was observed in the aforementioned PICS dataset (Schilling and Overall , 2008 ) . In the latter study, the authors report positive and negative cooperativity between P3 Leu and P1 Ala, and P3 Leu and P1 Phe residues, respectively, the dataset reported here, however, shows a slight preference for both amino acid pairs.
Taken together, we provide a list of human proteins cleaved in vitro by the HIV-1 protease. The identifi cation of known host substrates and the overlap with previous studies suggests processing of several proteins during HIV infection with a hint to factors involved in protein translation and RNA splicing. Our failure to delineate an effi cient substrate sequence based on the primary amino acid sequence illustrates the complex mechanisms involved in substrate recognition by the HIV-1 protease. Nevertheless, as the protein structures of several substrates in our catalogue have been resolved, our data could be of great value to the study of substrate recognition in detail by structural modeling and docking studies.
Materials and methods
Cell culture and SILAC labeling
Human Jurkat T-cells were purchased from the ATCC (TIB-152, American Type Culture Collection, Manassas, VA, USA) and grown in RPMI-1640 medium supplemented with 10 % dialyzed foetal bovine serum (Invitrogen, Carlsbad, CA, USA), 100 units/ml penicillin (Invitrogen) and 100 μ g/ml streptomycin (Invitrogen). Cells were cultured in SILAC media containing 12 C 6 (light) or 13 C 6 (heavy) Figure 6 iceLogo ) alignment and visualisation of all processed sequences identifi ed by N-terminal COFRADIC (n = 148) and PICS (n = 327) (Schilling and Overall , 2008 ) . The amino acid frequency at every subsite is compared to their frequency in the human proteins stored in the Swiss-Prot database (negative control). Only residues that are statistically over-represented (upper part of the iceLogo) or under-represented (lower part of the iceLogo) at the 95 % confi dence level are depicted. Residues that were never observed at specifi c positions are shown in pink. With both COFRADIC and PICS, the palindromic ELLE-motif was revealed as consensus sequence, refl ecting the homodimeric nature of the HIV-1 protease.
L-arginine (Cambridge Isotope Labs, Andover, MA, USA) (Ong et al. , 2002 ) at a reduced concentration (20 % of the normal concentration present in RPMI medium). Cells were held at 37 ° C in 5 % CO 2 for at least six population doublings to ensure complete incorporation of the arginine label.
N-terminal sample preparation
Samples were prepared as previously described Staes et al. , 2011 ) and outlined in Figure 2 . To maximize the number of identifi ed cleavage sites, the experiment was repeated three times, including label swapping. Briefl y, equal amounts of light-and heavy-labeled Jurkat T-cells were harvested, washed with PBS and lysed by three freeze-thaw cycles in 50 m m 2-( N -morpholino)ethanesulfonic acid (MES), 50 m m sodium phosphate, pH 7.4, 150 m m NaCl, 1 m m dithiothreitol (DTT) supplemented with an EDTA-free protease inhibitor tablet (Roche Diagnostics, Mannheim, Germany, 1 tablet per 100 ml). Heavy-and light-labeled lysates were centrifuged for 15 min at 16 000 g to remove insoluble components and the protein concentration in the supernatant was measured using the Biorad Protein Assay (Biorad Laboratories, Munich, Germany). Both lysates (each containing 1.5 mg total protein) were acidifi ed with 2 N HCl to pH 5.5, and NaCl was added to a fi nal concentration of 300 m m from a 5 m stock solution. Recombinant HIV-1 protease (ProteinOne, Bethesda, MD) was added to a fi nal concentration of 200 n m to either the light-or heavy-labeled lysate (treated sample), whereas no protease was added to the other lysate (control sample). Both samples were incubated for 75 min at 37 ° C, after which guanidinium hydrochloride was added to a fi nal concentration of 4 m to denature proteins and inhibit protease activity. The pH was again increased to 7.5 using 2 m NaOH followed by protein reduction and S-alkylation with 1 m m tris(2-carboxyethyl)phosphine (TCEP) and 2 m m iodoacetamide, respectively, and incubation for 60 min at 30 ° C. Excess reagents were removed by desalting on NAP ™ -10 desalting columns (Amersham Biosciences, Uppsala, Sweden) in 2 m guanidinium hydrochloride in 50 m m sodium phosphate buffer at pH 8.0 (sample volume was now 1.5 ml). The sample volume of both samples was reduced to 1 ml by vacuum drying and free amines were modifi ed by addition of an N-hydroxysuccinimide ester of trideutero-acetate [synthesized as described before (Staes et al. , 2011 ) ] to a fi nal concentration of 7.5 m m , followed by incubation for 2 h at 30 ° C. In both samples, O-acetylation was reversed by addition of hydroxylamine to a fi nal concentration of 30 m m and incubation for 10 min at room temperature, followed by quenching the excess of the N-hydroxysuccinimide ester by adding glycine to a fi nal concentration of 15 m m and incubation for another 10 min at room temperature. Equal amounts from both samples were mixed and this mixture was immediately desalted on PD-10 desalting columns (Amersham Biosciences) in 20 m m ammonium bicarbonate pH 8.0 (the sample was eluted in 3.5 ml). The sample volume was reduced to 2 ml by vacuum drying, and the protein mixture was boiled for 5 min and placed on ice for 5 min, after which 5 μ g of sequencing-grade trypsin (Promega, Madison, WI) was added for overnight digestion at 37 ° C. Subsequent selection of N-terminal and neo-N-terminal peptides by strong cation exchange chromatography and COFRADIC were performed as described previously (Staes et al. , 2008 (Staes et al. , , 2011 .
LC-MS/MS analyses, peptide identifi cation and quantifi cation
For processing of all MS data, the ms_lims software platform was used (Helsens et al. , 2010 ) . N-terminal peptides were analyzed on a Bruker Esquire HCT ion trap (Bruker Daltonics, Bremen, Germany) that was operated as described previously using identical parameters for MS/MS peak list generation by Bruker ' s DataAnalysis software (version 3.1) (Ghesquiere et al. , 2006 ) . In total, 88,997 MS/MS spectra were recorded and searched with MASCOT using the MASCOT Daemon interface (version 2.1.0) in the Swiss-Prot database (version 51 of UniProtKB/Swiss-Prot protein database containing 14 987 human protein sequences), as well as in N-terminally truncated peptide databases as previously described (Van Damme et al. , 2005 ) . For the protein database search, the taxonomy was set to human and the enzyme setting was ArgC/P, allowing for one missed cleavage. Mass tolerance of the precursor ions as well as fragment ions was set to 0.5 Da. The peptide charge parameter was set to 1 + , 2 + or 3 + and instrument settings were ESI-TRAP. Variable modifi cations were oxidation of methionine (sulfoxide), deamidation of asparagine and glutamine, pyroglutamate formation of N-terminal glutamine, pyrocarbamidomethyl formation of N-terminal cysteine and acetylation (both normal and trideutero-acetyl) of the N-terminus. Fixed modifications were carbamidomethylation of cysteines and trideutero-acetylation of lysine side-chains. To enable identifi cation of 13 C 6 -arginine containing peptides, searches were repeated with 13 C 6 -labeling of arginine as an additional fi xed modifi cation. 3581 MS/MS spectra Cleavage of the ELLE-motif was tested on peptide substrates that were analyzed by RP-HPLC and compared with the IFLE-motif discovered from phage display libraries (Beck et al. , 2000 ) . The recorded chromatograms (UV absorbance at 214 nm) are shown, clearly indicating less effi cient cleavage of the ELLE-motif. The sequences of the fl uorescently quenched peptides were Abz-GELELLELKDGY(NO 2 )R, Abz-GSGIFLETSLY(NO 2 )R, Abz-GSGELLETSLY(NO 2 )R (Abz: amino benzoic acid; Y(NO 2 ): nitrotyrosine).
were identifi ed and peptides were checked individually for the singleton status of potential neo-N-terminal peptides. Note that in all analyses, only peptides that were ranked fi rst and that scored above the threshold score set at 95 % confi dence were withheld. The FDR was calculated for every experiment as described previously (Kall et al. , 2008 ) and was always found to be lower than 3.7 % . Sequences of neo-N-terminal peptides assigned to HIV-1 protease activity (see main text) were re-mapped against a recent version of the SwissProt database (version 57 of UniProtKB/Swiss-Prot protein database containing 20,330 human protein sequences) to generate Table 1 . For every neo-N-terminal peptide, the highest scoring MS/MS spectrum (n = 148) was stored in the PRIDE database (experiment accession number 16377) using the PRIDE converter (Barsnes et al. , 2009 ).
Immunoblotting
Jurkat T-cell lysates were prepared and treated with recombinant HIV-1 protease (ProteinOne) as described previously with or without addition of Ac-pepstatin (Merck, Darmstadt, Germany), ritonavir (obtained through the NIH AIDS Research and Reference Reagent Program) and/or zVADfmk (Promega) at the indicated concentrations. Criterion XT gels and buffers (Bio-Rad) were used for SDS-PAGE. Equal amounts of total protein from the incubated cell lysates were loaded on individual gel lanes (20 to 30 μ g as measured with the Bio-Rad Protein Assay). Proteins were separated on 12 % or 4 -12 % Bis-Tris gels in MOPS or MES buffer at 150 V and transferred overnight in 50 m m Tris and 50 m m boric acid at 10 V onto a PVDF membrane. Protein detection was performed using the LI-COR Odyssey Infrared Imaging System according to the manufacturer ' s instruction (LI-COR Biosciences, Lincoln, NE). Primary antibodies against vimentin (Abcam, ab7783) and DDX5 (Abcam, ab21696) were diluted 500× and 1000× for protein detection, respectively.
Peptide cleavage assays
The following peptides were synthesized using Fmoc (N-(9-fl uorenyl) methoxycarbonyl) chemistry on an Applied Biosystems 443A Peptide Synthesizer: Abz-GELELLELKDGY(NO2)R (COFRADIC consensus), Abz-GSGIFLETSLY(NO 2 )R (Beck et al. , 2000 ) , Abz-GSGELLETSLY(NO 2 )R (COFRADIC/Beck hybrid) (Abz: amino benzoic acid; Y(NO 2 ): nitrotyrosine). Peptides were dissolved in assay buffer (50 m m MES pH 5.5, 300 m m NaCl, 1 m m DTT) at a concentration of 100 μ m and incubated for the time indicated with 200 n m rHIV-1 protease (ProteinOne, Bethesda, MD) at 37 ° C. Reactions were quenched in RP-HPLC solvent A (0.1 % trifl uoroacetic acid, 2 % acetonitrile in water) and monitored by recording the UV absorbance signal (214 nm) of the precursor peptide and its fragments during RP-HPLC separation.
